ApolloBio has signed an amended agreement to obtain exclusive development and commercialisation rights for Inovio Pharmaceuticals’ VGX-3100 in Greater China, comprising China, Hong Kong, Macao and Taiwan.
The agreement involves an option for potential inclusion of the Republic of Korea in the next three years.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
VGX-3100 is a DNA immunotherapy product formulated for the treatment of pre-cancers caused by human papillomavirus (HPV).
It is currently being developed as a non-surgical therapy for high-grade cervical dysplasia and associated underlying persistent HPV infection.
Under the latest agreement, Inovio will receive an upfront payment of $23m from ApolloBio, along with potential milestone payments of up to $20m in the future.
The deal, which replaces the original agreement signed in November last year, covers development of the product for treatment and/or prevention of pre-cancerous HPV infections and HPV-driven dysplasias such as cervical, vulvar and anal pre-cancers.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe amendment, however, excludes HPV-driven cancers and combinations of VGX-3100 with other immunostimulants.
Inovio Pharmaceuticals president and CEO Dr Joseph Kim said: “We are pleased to move forward with an agreement that preserves the best interest for our shareholders by obtaining a greater upfront non-dilutive cash licence fee of $23m and removing the equity provisions.
“In addition, this collaborative agreement with ApolloBio could potentially accelerate our overall global VGX-3100 efforts by accessing clinical study patients in China.”
The firm expects to close the agreement in the first quarter of this year.
